ArticleAntibiotics (Basel, Switzerland)2020
Antibacterial and Anti-Inflammatory Activity of an Antimicrobial Peptide Synthesized with D Amino Acids.
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Cooperative Oligomeric Peptide Combinations Enhance the Predicted Therapeutic Profile of SET-M33.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- SET-M33 peptide as a selectiveMicrobiology spectrum · 2026Article
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Antimicrobial Peptides SET-M33L and SET-M33L-PEG Are Promising Agents Against Strong Biofilm-FormingAntibiotics (Basel, Switzerland) · 2025Article
- The identity of implant materials governs the antimicrobial efficacy of SET-M33.Scientific reports · 2025Article
- Cutaneous wound healing functions of novel milk-derived antimicrobial peptides, hLFT-68 and hLFT-309 from human lactotransferrin, and bLGB-111 from bovine β-lactoglobulin.Scientific reports · 2025Article
- Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges.Journal of translational medicine · 2025Review
- EndophyticFrontiers in microbiology · 2025Article
- Branched tetrameric lactoferricin peptides modified with diaminopropionic acid exhibit potent antimicrobial and wound-healing activities.Frontiers in pharmacology · 2025Article
- Antibacterial and Anti-Inflammatory Activity of Branched Peptides Derived from Natural Host Defense Sequences.Journal of medicinal chemistry · 2024Article
- Antimicrobial Peptides towards Clinical Application-A Long History to Be Concluded.International journal of molecular sciences · 2024Review
- Article
- The Antimicrobial, Antibiofilm and Anti-Inflammatory Activities of P13#1, a Cathelicidin-like Achiral Peptoid.Pharmaceuticals (Basel, Switzerland) · 2023Article
- In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation.International journal of molecular sciences · 2023Article
- Advances of Antimicrobial Peptide-Based Biomaterials for the Treatment of Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Inhalable Polymeric Nanoparticles for Pulmonary Delivery of Antimicrobial Peptide SET-M33: Antibacterial Activity and Toxicity In Vitro and In Vivo.Pharmaceutics · 2022Article
- Cell-Penetrating Antimicrobial Peptides with Anti-Infective Activity against Intracellular Pathogens.Antibiotics (Basel, Switzerland) · 2022Review
- Safety evaluations of a synthetic antimicrobial peptide administered intravenously in rats and dogs.Scientific reports · 2022Article
- Antimicrobial Peptides Active in In Vitro Models of Endodontic Bacterial Infections Modulate Inflammation in Human Cardiac Fibroblasts.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peptide SET-M33 is a molecule synthesized in tetra-branched form which is being developed as a new antibiotic against Gram-negative bacteria. Its isomeric form with D amino acids instead of the L version (SET-M33D) is also able to kill Gram-positive bacteria because of its higher resistance to bacterial proteases (Falciani et al.,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.